Image may be NSFW.
Clik here to view.
Frequency Therapeutics said today that it closed a $42 million Series B round to support the clinical development of its hearing regeneration drug, FX-322.
The company is slated to publish top-line data from an ongoing Phase I/II study of FX-322 in the first half of the year.
Get the full story at our sister site, Drug Delivery Business News.
The post Frequency Therapeutics raises $42m for hearing regeneration drug appeared first on MassDevice.
